Frequent loss of heterozygosity on chromosome 5 in non-small cell lung carcinoma

P Mendes-da-Silva, A Moreira, J Duro-da-Costa, D Matias, C Monteiro

Abstract

Aims—Loss of heterozygosity (LOH) at specific chromosomal regions strongly suggests the existence of tumour suppressor genes at the relevant segment. Frequent LOH on chromosome 5q has been reported in a wide variety of human tumours, including those of the lung. The aim of this study was to screen for LOH and to clarify the location of putative tumour suppressor genes on chromosome 5 implicated in the genesis and/or development of non-small cell lung carcinoma.

Methods—Thirty three patients with advanced non-small cell lung carcinoma were screened for LOH with a panel of 21 microsatellite DNA markers spanning the entire chromosome 5, using semi-automated fluorochrome based methodology.

Results—Twenty of the non-small cell lung carcinoma samples displayed LOH for one or more informative locus. LOH involving only 5q was found in 10 of 14 of the informative samples. Deletions involving 5p only were not present in the samples under study. There was no evidence of microsatellite instability in any of the analysed loci. These results indicate the presence of five distinct segments displaying high frequencies of deletion on chromosome 5, namely: 5q11.2–q12.2, 5q15 (D5S644 locus), 5q22.3–q23.1, 5q31.1, and 5q35.3. Eight of 14 samples had simultaneous interstitial deletions in at least two different regions. Moreover, concomitant deletion of three and four distinct regions was displayed in three of 14 and two of 14, respectively, of the informative samples.

Conclusion—Allelic deletion on chromosome 5 is a frequent event in patients with non-small cell lung carcinoma. These results suggest the involvement of these five regions, either independently or simultaneously, in both lung squamous cell carcinoma and lung adenocarcinoma.

Keywords: non-small cell lung carcinoma; chromosome 5; loss of heterozygosity

Inactivation of tumour suppressor genes appears to be one of the genetic mechanisms involved in the development of solid tumours. This process includes mutation of one allele, followed by a deletion of the remaining one (loss of heterozygosity; LOH) or homozygous deletion of both alleles. Allelic deletions detected as LOH have proved useful for mapping regions of DNA that contain tumour suppressor genes.

In non-small cell lung cancer the chromosomes most frequently affected by LOH are 3p, 5q, 9p, 13q, and 17p.1

Chromosome 5 is a frequent target of genetic alterations in several malignant diseases such as ovarian cancer,2 gastric cancer,3 oesophageal cancer,4 and malignant myeloid diseases.5 LOH on chromosome 5 has been reported in non-small cell lung carcinoma, affecting both the p and q arms. Deletions involving the long arm of chromosome 5 include the APC/MCC gene cluster,6–8 the 5q33–q35 region9 and, more recently, the 5q11–q13 region containing the mismatch repair gene hMSH3.10 A candidate tumour suppressor gene locus on the short arm of chromosome 5, del-27, was reported to be deleted in non-small cell lung carcinoma and maps to the chromosomal segment 5p12–p13.11 Moreover, chromosome 5 is described as being a molecular target of carcinogens in the development of lung cancer, and the proportion of bleomycin induced 5q aberrations that survive in patients with lung cancer is significantly higher than in healthy controls.12

In our study, 21 (CA)n microsatellite markers were analysed in 33 matched normal/tumour samples from patients with non-small cell lung carcinoma using fluorescent DNA technology. Our objective was to screen for LOH and to clarify the location of putative tumour suppressor genes on chromosome 5 implicated in the genesis and/or development of non-small cell lung carcinoma.

Methods

TISSUE SAMPLES

Thirty three non-small cell lung carcinomas (25 squamous cell carcinomas and eight adenocarcinomas) and matched control constitutional DNAs were obtained from the Portuguese Institute of Oncology Dr Francisco Gentil, in Lisbon, from patients with locally advanced or metastatic disease not submitted to previous chemotherapeutic/radiotherapeutic treatments. Tumour samples were collected by fibre-optic bronchoscopy and control DNA
samples were obtained either from normal bronchial tissue not adjacent to the tumour or from blood. Both the neoplastic and normal cell content were analysed by histopathological methods. DNA from solid tissue was purified by proteinase K digestion, extracted with phenol/chloroform, and precipitated by ethanol. DNA from blood samples was obtained by the guanidine HCl method.

**ALLELOTYPING OF SHORT TANDEM REPEATS**

Twenty one short tandem repeat DNA markers for chromosome 5 (PE-ABD linkage set of markers) were obtained from Perkin Elmer-ABD (Foster City, California, USA) and amplified by the polymerase chain reaction (PCR) for LOH screening (table 1). One primer of each pair was fluoroscently labelled with a fluorochrome (TET, FAM, HEX, or JOE) attached to the 5' end. PCR reactions were carried out in a total volume of 20 µl containing 1× reaction buffer (10× PCR Buffer II; Perkin Elmer-ABD), 0.06–0.5 µM of each primer, 200 µM of each deoxynucleotide triphosphate (Pharmacia, Buckinghamshire, UK), 0.5 U of DNA polymerase (AmpliTaq Gold; Perkin Elmer-ABD), 1.0–2.0 mM of MgCl2 (Perkin Elmer-ABD), and 100–200 ng of genomic DNA. PCR amplifications were performed in a Perkin Elmer 9600 GenAmp PCR system and the conditions were 12 minutes at 95°C, followed by 15 seconds at 94°C, 15 seconds at 55/60°C, and 30 seconds at 72°C for 10 cycles, and by 15 seconds at 89°C, 15 seconds at 55/60°C, and 30 seconds at 72°C for 30 cycles, with a final extension step of 10 minutes at 72°C. Negative controls were incorporated into every PCR set of amplification for the detection of contamination.

PCR products were separated by 6% denaturing polyacrylamide gel electrophoresis in a 373A DNA sequencer (Perkin Elmer-ABD). All samples were tested at least twice in independent gel loadings. Microsatellite allele sizes were determined by reference to the internal lane standards 350-TAMRA or 350-ROX (Perkin Elmer-ABD) and the results were analysed using GeneScan 672 software (Perkin Elmer-ABD).

**Results and discussion**

LOH was evaluated using the formula \((T1 : T2/N1 : N2)\), with additional visual interpretation of both tumour and constitutional amplimer profiles (fig 1). LOH was defined as a reduction of at least 30% in one allele of the tumour DNA when compared with the constitutional DNA sample. LOH for one or more informative (heterozygous) locus was detected in 20 of the 33 non-small cell lung carcinoma samples. No significant differences in the proportions of samples displaying LOH were found between the squamous cell carcinoma samples and the adenocarcinoma samples (64% and 50%, respectively).

Six of 33 samples displayed LOH for all the informative loci, suggesting a reduction to monosomy of chromosome 5. Among the samples with interstitial deletions (fig 2), 10 of 14 displayed LOH involving 5q loci only and four of 14 showed LOH involving both 5p and 5q loci. Samples displaying LOH involving only the short arm of chromosome 5 were not found. Although minimal regions of deletion have been identified previously on 5p, namely del-27 on 5p12–p13, and the D5S667 locus on 5p15, 5p15.2, the 5p loci deleted in our samples seem to be involved in larger deletions, encompassing both the p and q arms of chromosome 5. Similar results have been reported for ovarian cancer and tumours of the papilla of Vater, in which the few losses in the short arm of chromosome 5 were not found in the 33 non-small cell lung carcinoma samples. No significant differences in the proportions of samples displaying LOH were found between the squamous cell carcinoma samples and the adenocarcinoma samples (64% and 50%, respectively).

**Table 1** LOH at chromosome 5

<table>
<thead>
<tr>
<th>Locus</th>
<th>Map location</th>
<th>Distance to the next marker (cM)</th>
<th>Informative cases</th>
<th>LOH %</th>
</tr>
</thead>
<tbody>
<tr>
<td>D5S406</td>
<td>5p15.31</td>
<td>32.7</td>
<td>9</td>
<td>0.0</td>
</tr>
<tr>
<td>D5S419</td>
<td>5p14.3</td>
<td>12.8</td>
<td>19</td>
<td>10.5</td>
</tr>
<tr>
<td>D5S426</td>
<td>5p11</td>
<td>12.7</td>
<td>12</td>
<td>8.3</td>
</tr>
<tr>
<td>D5S407</td>
<td>5q11.2</td>
<td>9.8</td>
<td>17</td>
<td>52.9</td>
</tr>
<tr>
<td>D5S647</td>
<td>5q11.2</td>
<td>10.2</td>
<td>18</td>
<td>9</td>
</tr>
<tr>
<td>D5S122</td>
<td>5q12.2</td>
<td>14.3</td>
<td>13</td>
<td>6</td>
</tr>
<tr>
<td>D5S428</td>
<td>5q14.1</td>
<td>10.5</td>
<td>17</td>
<td>5</td>
</tr>
<tr>
<td>D5S644</td>
<td>5q15</td>
<td>4.4</td>
<td>24</td>
<td>11</td>
</tr>
<tr>
<td>D5S299</td>
<td>5q21.3</td>
<td>2.5</td>
<td>24</td>
<td>6</td>
</tr>
<tr>
<td>D5S433</td>
<td>5q21.3</td>
<td>0.6</td>
<td>22</td>
<td>9</td>
</tr>
<tr>
<td>D5S356</td>
<td>5q22.3</td>
<td>0.6</td>
<td>26</td>
<td>9</td>
</tr>
<tr>
<td>D5S427</td>
<td>5q25.1</td>
<td>0.5</td>
<td>22</td>
<td>9</td>
</tr>
<tr>
<td>MCC</td>
<td>5q25.1</td>
<td>1.0</td>
<td>20</td>
<td>9</td>
</tr>
<tr>
<td>D5S318</td>
<td>5q25.1</td>
<td>16.0</td>
<td>21</td>
<td>8</td>
</tr>
<tr>
<td>D5S393</td>
<td>5q31.1</td>
<td>9.0</td>
<td>15</td>
<td>5</td>
</tr>
<tr>
<td>D5S436</td>
<td>5q31.1</td>
<td>8.5</td>
<td>14</td>
<td>6</td>
</tr>
<tr>
<td>D5S673</td>
<td>5q31.1</td>
<td>7.2</td>
<td>11</td>
<td>8</td>
</tr>
<tr>
<td>D5S422</td>
<td>5q34</td>
<td>13.4</td>
<td>14</td>
<td>6</td>
</tr>
<tr>
<td>D5S400</td>
<td>5q35.2</td>
<td>4.7</td>
<td>12</td>
<td>3</td>
</tr>
<tr>
<td>D5S429</td>
<td>5q35.3</td>
<td>13.7</td>
<td>18</td>
<td>10</td>
</tr>
<tr>
<td>D5S408</td>
<td>5q35.3</td>
<td>9.8 (qter)</td>
<td>18</td>
<td>8</td>
</tr>
</tbody>
</table>

LOH, loss of heterozygosity.

**Figure 1** Retention and loss of heterozygosity (LOH). (A) Example of a sample showing retention of heterozygosity; the normal and tumour DNA profiles are identical. (B) Example of a sample displaying LOH; an arrow indicates a reduction in one of the tumour alleles when compared with the matched constitutional DNA.
5 were involved in the largest chromosomal deletions.

We also searched for microsatellite instability, in the form of deletion or expansion of dinucleotide repeats. None of the loci analysed displayed an alteration in the number of CA repeats and, therefore, we found no evidence of the RER+ phenotype in the cases under study. In fact, putting together our results and the ones reviewed elsewhere, the RER+ phenotype seems to be an infrequent event in non-small cell lung tumorigenesis.

Analysis of the deletion map (fig 2), together with the frequency of LOH obtained for each locus (table 1) allowed us to identify five regions on chromosome 5 displaying high rates of LOH.

The 5q11.2–q12.2 region, which encompasses the hMSH3 mismatch repair gene locus (5q11–q12), was deleted in approximately half of the informative cases. This gene is reported to be hemizygously deleted in 42% of non-small cell lung carcinoma samples, but no inactivating mutation in the residual hMSH3 allele was found. The hMSH3 protein is involved in heteromolecular complexes and, therefore, the authors suggested that it could play a role in lung tumorigenesis by a mechanism of dosage effect, affecting cellular functions other than the mismatch repair activity, because the RER+ phenotype was found very infrequently in the samples under study. Our data seem to agree with this hypothesis because we found no microsatellite instability in the samples with deletions encompassing the hMSH3 locus. Further studies to screen for mutations in the remaining allele are necessary to clarify the hMSH3 inactivation state.

LOH at the D5S644 locus (5q15) was detected in nearly half of the informative tumours. This region is proximal to the APC locus, so that this gene can be excluded as the candidate tumour suppressor gene in this region. To our knowledge, this is the first report implicating 5q15 in non-small cell lung carcinoma. A previous study in ovarian cancer defined a 22 cM interval on 5q13.1–q21, which also did not encompass the APC locus, supporting the hypothesis of a candidate tumour suppressor gene in this region of chromosome 5.

Our study also identified the 5q22.3–q23.1 region as being frequently deleted in non-small cell lung carcinoma. Analysis of the deletion map (fig 2; cases 102 and 139) indicates that the minimal region of deletion might be flanked by markers D5S346 and D5S318, defining a 2 cM segment that encompasses the APC and MCC loci. Ashton-Rickardt and colleagues and D’Amico and colleagues were the first authors to describe the APC/MCC region as being frequently deleted in lung cancer. Since then, several reports have indicated a high frequency of LOH at this region. Nevertheless, to date, no mutations have been reported in these genes. Moreover, several other genes have been cloned in this area, increasing the number of possible candidate tumour suppressor genes in this interval.

The 5q31.1 region has been reported as a target for frequent deletion in the myelodysplastic syndrome, oesophageal cancer, and gastric cancer. Within this region is the gene encoding interferon regulatory factor 1 (IRF-1), which functions as a tumour suppressor gene and is functionally inactivated in myelodysplastic syndrome and gastric cancer. The IRF-1 locus has not yet been implicated in lung tumorigenesis, but the high frequency of LOH on 5q31.1 obtained in our study makes IRF-1 a strong candidate for a tumour suppressor gene at this region.

The q telomere of chromosome 5 (5q33–q35) has been implicated previously in non-small cell lung carcinoma. Our study reveals a very high frequency of LOH in a more telomeric region, 5q35.3, not yet implicated in non-small cell lung carcinoma.

Loss of more than one region in the same tumour sample was seen in eight of 14 informative cases. We also found the concomitant deletion of three and four of the above regions.
mentioned regions in three of 14 and two of 14, respectively, of the informative samples. Dele-
tions simultaneously involving two, three, and four of the above mentioned regions were
found in both histological subtypes (fig 2), sug-
esting the involvement of more than one of
these regions, either independently or simulta-
neously, in the genesis and/or development of
non-small cell lung carcinoma.

This study was funded by PRODEP, CIENCIA/PRAXIS XXI,
Liga Portuguesa Contra o Cancer-Nucleo Sul, CEM/UNL.
We are also grateful to Perkin Elmer-ABD for providing the
linkage set of markers for chromosome 5.

1 Giaccone G. Oncogenes and antioncogenes in lung tumori-
2 Tavassoli F, Steinbrinkdottir H, Pierce E, et al. Loss of het-
erozygosity on chromosome 3q in ovarian cancer is
frequently accompanied by TP53 mutation and identifies a
3 Tamura G, Ogasawara S, Nishizuka S, et al. Two distinct
regions of deletion on the long arm of chromosome 5 in
differentiated adenocarcinomas of the stomach. Cancer Res
deleted region on the long arm of chromosome 5 in
chain reaction-based diagnosis of del (5q) in acute myeloid
leukemia and myelodysplastic syndrome identifies a
6 Ashton-Rickardt PG, Wylie AH, Bird CG, et al. MCC, a
candidate familial polyposis gene in 5q.21, shows frequent
allele loss in colorectal and lung cancer. Oncogene
sites within the MCC and APC loci reveal very frequent
loss of heterozygosity in human small cell lung cancer.
8 Hosoe S, Uen K, Shigedo Y, et al. A frequent deletion of
chromosome 5q21 in advanced small cell and non-small
9 Fong KM, Zimmerman PV, Smith J. Microsatellite instabil-
ity and other molecular abnormalities in non-small cell
Frequent loss of heterozygosity on chromosome 5 in non-small cell lung carcinoma

P Mendes-da-Silva, A Moreira, J Duro-da-Costa, D Matias and C Monteiro

doi: 10.1136/mp.53.4.184

Updated information and services can be found at:
http://mp.bmj.com/content/53/4/184

These include:

**References**
This article cites 23 articles, 8 of which you can access for free at:
http://mp.bmj.com/content/53/4/184#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/